依巴斯汀联合润燥止痒胶囊治疗慢性荨麻疹的临床观察  

Clinical observation on ebastine combined with Runzao Zhiyang capsule in treatment of chronic urticaria

作　　者：王军[1] 边鹊桥[1] 张淑环[1] 刘勇[1] 李钦峰[2] Wang J;Bian QQ;Zhang SH;Liu Y;Li QF(Department of Dermatology,Tianjin Third Central Hospital,Tianjin Institute of Hepatobiliary Disease,Tianjin Key Laboratory of Artifical Cell,Artifical Cell Engineering Technology Research Center of Public Health Ministry,Tianjin 300170,China;Department of Dermatology,Tianjin Children＇s Hospital,Tianjin 300074,Chin)

机构地区：[1]天津市第三中心医院皮肤性病科,天津市肝胆疾病研究所,天津市人工细胞重点实验室,卫生部人工细胞工程技术研究中心,300170 [2]天津市儿童医院皮肤科,300074

出　　处：《中国中西医结合急救杂志》2018年第3期308-310,共3页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：天津市医药卫生科技基金项目（2012KZ029）

摘　　要：目的观察依巴斯汀联合润燥止痒胶囊治疗慢性荨麻疹的临床疗效。方法选择2015年1月至2017月5月天津市第三中心医院皮肤性病科收治的慢性荨麻疹患者126例，按随机数字表法分为两组，对照组（62例）口服依巴斯汀10mg、每日1次，观察组（64例）在对照组基础上加服润燥止痒胶囊2g、每日3次，疗程4周。观察两组临床疗效和患者症状积分[荨麻疹活动性评分（UAS）、皮肤病生活质量指数（DLQI）评分]的变化；记录不良反应发生情况，停药4周随访复发情况。结果与对照组比较，观察组治疗后总湿效率明显升高[92．2％（59／64）比79．0％（49／62），P〈0．05]。两组治疗后UAS及DLQI评分均较治疗前明显降低，且以观察组的降低程度较对照组更显著[UAS（分）：1．26（0．52～7．35）比1．68（0．75～8．65），DLQI评分（分）：0，56±0．52比1．57±0．96，P〈0．01]；观察组治疗后总疗效症状积分下降指数（SSRI）明显高于对照组【（76±21）％比（69±23）％]，不良反应发生率[7．8％（5／64）比12．8％（8／62）]和复发率【8．3％（3／64）比23．8％（5／62）]均低于对照组（均P〈0．05）。结论依巴斯汀联合润燥止痒胶囊治疗慢性荨麻疹疗效显著，优于单独使用依巴斯汀，能明显提高临床疗效，减少不良反应的发生。Objective To observe the clinical efficacy of ebastine combined with Runzao Zhiyang capsules in the treatment of patients with chronic urticaria. Methods A total of 126 patients with chronic urticaria admitted to Department of Dermatology of Tianjin Third Central Hospital from January 2015 to May 2017 were enrolled and they were divided into two groups by the random number table method. The patients in control group （62 eases） were given oral ebastine administration 10 mg once per day, and those in observation group （64 cases） received oral administration of ebastine 10 mg once per day combined with Runzao Zhiyang capsule 2 g, 3 times per day, the therapeutic course being 4 weeks. The changes of clinical efficacy and the symptom scores, including urticaria activity score （UAS） and dermatolo-gical disease life quality index （DLQI） scores of the two groups were observed after treatment of 4 weeks; the incidence of adverse reactions and the recurrence situation after drug withdrawal for 4 weeks at follow-up were analyzed. Results Compared with the control group, the total effective rate of the observation group was significantly increased [92.2% （59/64） vs. 79.0% （49/62）, P 〈 0.05]. After treatment, the overall UAS score and DLQI score in two groups were both significantly decreased, the degree of decrease in observation group were more siginificant than those in control group [UAS： 1.26 （0.52 - 7.35） vs. 1.68 （0.75 - 8.65）, DLQI： 0.56±0.52 vs. 1.57 ±0.96, P 〈 0.01]. In addition, the total decrease degree of symptom score reducing index （SSRI） in the observation group was significantly greater than that in the control group [（76 ±21）% vs. （69 ± 23）%, P 〈 0.05], the incidence of adverse reactions [7.8% （5/64） vs. 12.8% （8/62）] and recurrence rate [8.3% （3/64） vs. 23.8% （5/62）] in the observation group were obviously lower than those in the control group （both P 〈 0.05）. Conclusion The efficacy of ebastine combined with Runzao Zhiyang caps

关 键 词：依巴斯汀 润燥止痒胶囊 慢性荨麻疹 效果 

分 类 号：R275.983.1[医药卫生—中西医结合]